Exploring the Role of Oral JAK Inhibitors in Atopic Dermatitis - Episode 5

Communicating With Patients on the Safety of JAK Inhibitors in Atopic Dermatitis

Published on: April 4, 2025

Linda Stein Gold, MD, Lisa Swanson, MD, PhD, James Song, MD, Christopher G. Bunick, MD, PhD

Experts discuss how to effectively communicate the safety of JAK inhibitors to patients with atopic dermatitis, including how to address the FDA boxed warning by emphasizing the balance of risks and benefits and tailoring the conversation based on individual patient concerns and risk factors.

EP. 1: The Role of the JAK/STAT Signaling Pathway in Atopic Dermatitis

EP. 2: JAK1 Selective Inhibition and the Impact of Selectivity on Efficacy and Safety

EP. 3: Long-Term Efficacy and Safety of JAK Inhibitors in Atopic Dermatitis

EP. 4: Understanding the Origins of the Boxed Warning for JAK Inhibitors

Now Viewing

EP. 5: Communicating With Patients on the Safety of JAK Inhibitors in Atopic Dermatitis

EP. 6: Laboratory Monitoring Plans for Oral JAK Inhibitors

Video content above is prompted by the following:

How do you talk to your patients about the safety of JAK inhibitors in atopic dermatitis? How do you navigate the discussion regarding the boxed warning?